Gorman S D, Clark M R
Department of Pathology, Cambridge University, UK.
Semin Immunol. 1990 Nov;2(6):457-66.
Monoclonal antibodies are playing an increasing role in many experimental therapies. A major limitation of their use is that they are recognised by the patient as being of foreign origin and an antiglobulin response is provoked. Recombinant DNA technology offers the ability to convert these rodent antibodies into a more human form. Different degrees of humanisation can be achieved ranging from chimeric antibodies with a combination of human constant regions with rodent variable regions to fully reshaped antibodies where the variable regions are also humanised. Encouraging preliminary results have been obtained and it seems likely that these will dictate the use of humanisation as a required procedure in the therapeutic use of monoclonal antibodies.
单克隆抗体在许多实验性治疗中发挥着越来越重要的作用。其使用的一个主要限制是，患者会将它们识别为外来物质，从而引发抗球蛋白反应。重组DNA技术能够将这些啮齿动物抗体转化为更具人类特性的形式。可以实现不同程度的人源化，从具有人类恒定区与啮齿动物可变区组合的嵌合抗体，到可变区也实现人源化的完全重塑抗体。已经获得了令人鼓舞的初步结果，而且这些结果似乎可能决定在单克隆抗体治疗应用中将人源化作为一项必要程序。
